Use access key #2 to skip to page content.
$8.74 -0.52 (-5.62%)
10/7/2008 3:44 PM

BioMimetic Therapeutics, Inc. (BMTI)

CAPS Rating:
**

The Company develops and commercializes bio-active drug-device combination products for the healing of musculoskeletal injuries and diseases, including periodontal, orthopedic, spine and sports injury applications.

View All Commentary (BMTI)

Recs

0

Avatar tiobueno (98.38) Submitted: 4/04/08 12:40 PM : Outperform Start Price: $9.70 BMTI Score: 17.37

April 1, 2008 11:00 AM EDT

BioMimetic Therapeutics Inc. (Nasdaq: BMTI) sees some concentrated insider buying:

CFO, Lawrence E. Bullock, bought 10,000 shares on 03/28
Officer, Earl Martin Douglas, bught 1,000 shares on 03/28
Director, Gary E Friedlender, bought 8,500 shares on 03/28
Director, James Murphy, bought 5,000 shares on 03/28
CEO, Samual E. Lynch, bought 5,400 shares on 03/28.

BioMimetic fell 56% last Thursday related to an FDA safety review of Regranex, a Johnson & Johnson product, which contains the same drug product (becaplermin) as BioMimetic's product candidates. [LJ]

Report this Post Replies: 0 | Reply

Featured Broker Partners